London
The King’s College London/Royal Free/UCL Gene Therapy Hub
The King’s College London/Royal Free/UCL Hub, led by Professor Robin Ali, will provide a comprehensive capability for clinical grade viral vector manufacturing. This will include adeno-associated viruses (AAV) , lentiviruses (LV) and Retroviruses (RV), production for early-phase trials, alongside substantial programmes in process innovation, knowledge transfer, and training to address critical skills shortages. In partnership with the network of Innovation Hubs, our vision is to ensure that the UK capitalises on its outstanding academic medical research to deliver novel gene therapies to patients, providing transformative treatments for currently intractable conditions, and generating a vibrant economic landscape.
Key People
London IHfGT Leadership Team:
- Hub's Director: Prof Robin Ali
- Chairman of KCL GTVF Board: Prof Simon Howell
- Hub's Operational Director: Kate Barlow
Supported by KCL GTVF Management:
- GTVF Operational Director: Dr Keith Meaney
- GTVF Head of Projects: Dr Joanna Przysowa
- GTVF Head of Business Development: Dr Henry Pegram
Work Package Leaders:
- Head of LV Production: Dr Sabine Domning (KCL)
- Head of AAV Delivery: Ferdos Hashi (KCL)
- Process Development Co-Lead: Prof Mark Lowdell (RF)
- Process Development Co-Lead: Dr Hemant Dhamne (KCL)
- Director of Skills & Training: Dr Francesca Gliubich (KCL)
- Skills & Training Co-Lead: Prof Qasim Rafiq (UCL)